DDS Collaborative Research
Details of DDS Collaboration
In the course of research and development of drugs, we have developed various DDS carriers such as emulsions, liposomes, and polymeric nanoparticles, and have encapsulated various compounds in these carriers with high efficiency. Furthermore, we have succeeded in improving the pharmacokinetics of protein formulations by modifying not only the carriers but also the protein with lipids. From these studies, we have gained the know-how and experience to bring DDS technology to clinical trials and market launch.
On the other hand, we believe that universities and public research institutes have many DDS technologies that can contribute to human health if nurtured successfully. For example, basic researchers who have discovered and synthesized ligands for receptors that are overexpressed or specifically expressed at disease sites or in specific organs, or novel functional compounds that can control drug release through intracellular transport control or stimulus responses such as pH or temperature changes, would like to use these to develop DDS and bring it to the clinical development stage.
Even if you bring a compound to a pharmaceutical company at such a basic research stage and apply for a joint research, it may be difficult to be accepted, isn’t it? This is due to the enormous time and cost required to advance from basic research to clinical trials, the establishment of manufacturing methods for mass production, and insufficient experimental data for practical application.
Therefore, we have launched a business to support the selection of optimal experimental methods from the basic research stage for patenting and licensing, as well as the development leading to manufacturing in pharmaceutical companies based on GMP standards, safety, and working examples. In addition, if an applicant has a novel ligand with excellent disease site/organ integration or a novel functional compound with controllable intracellular kinetics and drug release, but has limited experience in DDS carrier development, we can use our accumulated know-how and research equipment related to DDS carrier development We can also use our accumulated know-how and research equipment for the development of DDS carriers.
For researchers in academia, it is extremely difficult to conduct formulation manufacturing, patent prosecution, and negotiation of license-outs. We have experienced researchers in pharmaceutical companies and DDS drug development, as well as experts in each step of the process, such as intellectual property and clinical trials. Therefore, by utilizing our know-how and the cooperation of our experts, we are able to efficiently advance your research results to out-licensing. We can also receive a portion of the IP in exchange for a fee. Please feel free to contact us.
DDS Collaborative Research Achievements
We have launched our DDS products, Lipo-PGE1 and Lipo-NSAID.
Lipo-PGE1 is a DDS formulation that prevents PGE1 inactivation by encapsulating it in lipid emulsion and targeting it to the site of disease. We have successfully applied this technology to the development of several lipo-NSAIDs and other lipo-particulate formulations.
Binding of phospholipids to SOD (superoxide dismutase) (lecithinization),
PC-SOD, a DDS formulation with dramatically enhanced pharmaceutical activity, has been developed.
We are the only company with protein lecithinization technology, and this technology can be adapted to other proteins (e.g., antibodies).
The world’s first DDS stealth nanoparticles that simultaneously achieve both targeting (selective delivery of drug to the site of disease) and sustained release (gradual release of drug)
The nanoparticles containing PGE1 (nano-PGE1) will accumulate in vascular lesions and release PGE1 there, and are expected to exhibit higher efficacy with smaller doses and fewer administrations than the lipo-PGE1 we have marketed. These particles can be applied not only to low molecular weight compounds but also to nucleic acids and peptides.
